Clinical Trial Update: A Safety Extension Study of DR-OXY-301 [Phase 3]

View source ↗

Summary

Phase 3 safety extension study update for DR-OXY-301 in overactive bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• DR-OXY-301

Snippet

Sponsor: Duramed Research | Conditions: Overactive Bladder | Phase 3 | Status: COMPLETED